A spin-off from the Center for Biologic Nanotechnology at the University of Michigan, and initially focused on developing nano-scale dermatology applications. Applicant for SBIR-STTR Support under the name of Nanobio Corporation, soon after.the name of the company was changed to BlueWillow Biologics better to reflects evolution towards the focus on vaccines and advancing the firm's novel intranasal technology to develop new vaccines for several respiratory and sexually transmitted diseases. BlueWillow Biologics® is a privately-held biopharmaceutical company organized around developing and commercializing vaccines using its patented NanoVax® technology platform. The technology employs a novel oil-in-water nanoemulsion adjuvant that is effective when administered via intranasal or intramuscular vaccination, and can elicit both mucosal and systemic immunity when applied intranasally. BlueWillow is currently developing intranasal vaccines for several respiratory and sexually transmitted infections, including RSV, pertussis, influenza, anthrax, prophylactic and therapeutic HSV-2 and chlamydia.
